Overview of pharmacoeconomic modelling methods

被引：27

作者：

Ademi, Zanfina ^{[1
]}

Kim, Hansoo ^{[1
]}

Zomer, Ella ^{[2
]}

Reid, Christopher M. ^{[2
]}

Hollingsworth, Bruce ^{[3
]}

Liew, Danny ^{[1
]}

机构：

[1] Univ Melbourne, Dept Med RMH, Melbourne EpiCtr, Melbourne, Vic 3010, Australia

[2] Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic, Australia

[3] Univ Lancaster, Div Hlth Res, Lancaster, England

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 75卷 / 04期

基金：

英国医学研究理事会; 澳大利亚研究理事会;

关键词：

decision analysis; Markov modelling; pharmacoeconomics; uncertainty analyses; ECONOMIC-EVALUATION; DECISION-ANALYSIS; HEALTH; UNCERTAINTY; STRATEGIES;

D O I：

10.1111/j.1365-2125.2012.04421.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the current climate of burgeoning health care costs, pharmacoeconomics is becoming increasingly important, but knowledge about pharmacoeconomic methods is limited among most clinicians. This review provides an introduction to, and overview of, common methods used in pharmacoeconomic modelling: decision analysis, Markov modelling, discounting and uncertainty analyses via Monte Carlo simulation. It will conclude with a suggested approach to reading and appraising published pharmacoeconomic analyses.

引用

页码：944 / 950

页数：7

共 17 条

[1] An introduction to Markov modelling for economic evaluation [J].

Briggs, A ;

Sculpher, M .

PHARMACOECONOMICS, 1998, 13 (04) :397-409

[2] Handling uncertainty in cost-effectiveness models [J].

Briggs, AH .

PHARMACOECONOMICS, 2000, 17 (05) :479-500

[3]

Drummond MF, 2005, Methods for The Economic Evaluation of Health Care Programmes

[4] Decision analysis in patient care [J].

Elwin, G ;

Edwards, A ;

Eccles, M ;

Rovner, D .

LANCET, 2001, 358 (9281) :571-574

[5] EFFICACY AND EFFECTIVENESS TRIALS (AND OTHER PHASES OF RESEARCH) IN THE DEVELOPMENT OF HEALTH PROMOTION PROGRAMS [J].

FLAY, BR .

PREVENTIVE MEDICINE, 1986, 15 (05) :451-474

[6] Calibrating Models in Economic Evaluation A Comparison of Alternative Measures of Goodness of Fit, Parameter Search Strategies and Convergence Criteria [J].

Karnon, Jonathan ;

Vanni, Tazio .

PHARMACOECONOMICS, 2011, 29 (01) :51-62

[7] Epidemiological modelling (including economic modelling) and its role in preventive drug therapy [J].

Liew, D ;

McNeil, JJ ;

Peeters, A ;

Lim, SS ;

Vos, T .

MEDICAL JOURNAL OF AUSTRALIA, 2002, 177 (07) :364-367

[8] A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease [J].

Liew, Danny ;

Lim, Stephen S. ;

Bertram, Melanie ;

McNeil, John J. ;

Vos, Theo .

EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2006, 13 (04) :515-522

[9]

Lilford RJ, 1998, BMJ-BRIT MED J, V317, P405

[10] The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis [J].

Montgomery, AA ;

Fahey, T ;

Ben-Shlomo, Y ;

Harding, J .

JOURNAL OF HYPERTENSION, 2003, 21 (09) :1753-1759

← 1 2 →